Intra-Cellular’s schizophrenia drug meets main goal in late-stage trial
By Thomson ReutersNov 5, 2024 | 6:13 AM
(Reuters) – Intra-Cellular Therapies said on Tuesday its drug to prevent relapses in schizophrenia patients met the main goal of a late-stage trial.
(Reporting by Christy Santhosh in Bengaluru; Editing by Savio D’Souza)
For the health and safety of everyone, our offices are temporarily closed to the public. If you have won a prize from us we will be mailing it to you or will contact you with specific information needed to redeem your prize. Feel free to call us with questions during weekday business hours at 715-842-1672.
